Laurent Bourguignon
Overview
Explore the profile of Laurent Bourguignon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
597
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Collomb E, Bourguignon L, Tichadou A, Roche P, Berton G, Ciccolini J, et al.
Hematol Oncol
. 2025 Mar;
43(2):e70057.
PMID: 40088477
No abstract available.
2.
Mashal M, Guitton J, Sallet P, Bourguignon L, Machon C
Drug Test Anal
. 2024 Aug;
PMID: 39148281
Monitoring of drug use in athletes is of interest both for health and competition-related issues. Considering the advantages of Dried Blood Sampling (low invasiveness, easy sampling, long term storage), we...
3.
Boulekbache A, Maldonado F, Kavafian R, Ferry T, Bourguignon L, Goutelle S, et al.
J Antimicrob Chemother
. 2024 Feb;
79(4):712-721.
PMID: 38323372
Background: The indications of daptomycin have been extended to off-label indications including prosthesis-related infection, and bone and joint infection (BJI). However, efficacy and safety have not been thoroughly demonstrated compared...
4.
Garreau R, Pham T, Bourguignon L, Millet A, Parant F, Bussy D, et al.
Clin Infect Dis
. 2024 Jan;
79(4):1121-1122.
PMID: 38236297
No abstract available.
5.
Goutelle S, Wallet F, Thoma Y, Peclard J, Bourguignon L, Cohen S, et al.
Anaesth Crit Care Pain Med
. 2023 Jul;
42(6):101286.
PMID: 37517689
No abstract available.
6.
Garreau R, Pham T, Bourguignon L, Millet A, Parant F, Bussy D, et al.
Clin Infect Dis
. 2023 Jul;
77(10):1372-1380.
PMID: 37467019
Background: High-dose daptomycin is increasingly used in patients with bone and joint infection (BJI). This raises concerns about a higher risk of adverse events (AEs), including daptomycin-induced eosinophilic pneumonia (DIEP)...
7.
Tuloup V, Goutelle S, Tod M, Bourguignon L
Clin Pharmacokinet
. 2023 Jan;
62(2):307-319.
PMID: 36631686
Background And Objective: Chronic kidney disease (CKD) may alter drug renal elimination but is also known for interacting with hepatic metabolism via multiple uremic components. However, few global models, considering...
8.
Cauvin C, Bourguignon L, Carriat L, Mence A, Ghipponi P, Salas S, et al.
Pharmaceutics
. 2022 Nov;
14(11).
PMID: 36432700
Background: Cisplatin is a pivotal drug in the treatment of head and neck cancer, and personalized dosage should help the preservation of an optimal toxicity-efficacy ratio. Methods: We analyzed the...
9.
De La Gastine B, Percevault S, Varin L, Richard N, Fobe F, Plaud B, et al.
Pharmaceutics
. 2022 Oct;
14(10).
PMID: 36297612
Cytochrome P450 2D6 (CYP2D6) gene polymorphisms influence the exposure to tramadol (T) and its pharmacologically active metabolite, O-demethyl tramadol (O-dT). Tramadol has been considered as a candidate probe drug for...
10.
Reverchon J, Tuloup V, Garreau R, Nave V, Cohen S, Reix P, et al.
Pharmaceutics
. 2022 Aug;
14(8).
PMID: 36015375
Therapeutic drug monitoring (TDM) of tobramycin is widely performed in patients with cystic fibrosis (CF), but little is known about the value of model-informed precision dosing (MIPD) in this setting....